Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 2,650 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical Clear all
Completed Phase 2 Interventional

Topical PluroGel N for the Treatment of Mildly Infected Diabetic Foot Ulcers

NCT02091596
View directory record Official record
Conditions
Diabetic Foot Ulcer, Infection
Interventions
PluroGel N, PluroGel
Drug
Lead sponsor
PluroGen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 23, 2026, 6:48 AM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Polyethylene-glycol Assisted Nerve Repair in Phalloplasty

NCT05897086
View directory record Official record
Conditions
Gender Dysphoria
Interventions
Polyethylene Glycol 3350
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

NCT04052425
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
29
States / cities
Hoover, Alabama • Scottsdale, Arizona • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 1 Interventional

Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon

NCT00700518
View directory record Official record
Conditions
Raynaud's Phenomenon
Interventions
placebo cream, Glyceryl Trinitrate
Drug
Lead sponsor
Procris Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 30, 2008 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Starting a Testosterone and Exercise Program After Hip Injury

NCT02938923
View directory record Official record
Conditions
Hip Fracture, Frailty, Sarcopenia
Interventions
Testosterone, Placebo gel, Supervised exercise training, Home exercise program, Health Education Modules
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Aurora, Colorado • Farmington, Connecticut • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Topical SLPI on Skin Wounds

NCT00005569
View directory record Official record
Conditions
Healthy, Wound Healing
Interventions
SLPI (Secretory Leukocyte Protease Inhibitor)
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

NCT04268069
View directory record Official record
Conditions
Dry Eye Disease
Interventions
PL9643 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Andover, Massachusetts • Raynham, Massachusetts • Shelby, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 23, 2026, 6:48 AM EDT
Recruiting Phase 2 Interventional

Tirzepatide for Treatment of CCCA

NCT07734870
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
Tirzepatide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration

NCT06927960
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
AH-001 or placebo
Drug
Lead sponsor
AnHorn Medicines Co. Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Not applicable Interventional

Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%

NCT02752646
View directory record Official record
Conditions
Cataract
Interventions
nepafenac 0.3%, ketorolac
Drug
Lead sponsor
MDbackline, LLC
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Laguna Hills, California • Edgewood, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing Tattoo Removal: a Side-by-side Comparison in the Search for One Treatment Tattoo Removal

NCT01624688
View directory record Official record
Conditions
Tattoo, Tattoo Removal
Interventions
Tattoo Removal
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 4 Interventional Results available

SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty

NCT05919888
View directory record Official record
Conditions
Surgery, Surgical Site Infection, Cutibacterium Acnes, Prosthetic-joint Infection
Interventions
Povidone-Iodine, SURGX Wound Gel
Drug · Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 1 Interventional

The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma

NCT00943982
View directory record Official record
Conditions
Uveitis
Interventions
Interferon Gamma 1-b
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 2 Interventional

A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy

NCT04786340
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetes Mellitus
Interventions
Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution, Placebo: WST-057 4mL topical solution
Drug
Lead sponsor
WinSanTor, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 23, 2026, 6:48 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

NCT06073132
View directory record Official record
Conditions
Generalized Epidermolysis Bullosa Simplex
Interventions
AC-203, Vehicle
Drug
Lead sponsor
TWi Biotechnology, Inc.
Industry
Eligibility
6 Months and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Rancho Santa Margarita, California • Stanford, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

A Study Designed to Evaluate Tear Production

NCT06544707
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

NCT01555463
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic acid foam, 15% (BAY39-6251), Vehicle foam
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
49
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 4 Interventional Results available

Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses

NCT00774787
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod 5% cream
Drug
Lead sponsor
Rigel Dermatology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
St. Petersburg, Florida • Henderson, Nevada • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 4 Interventional

2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery

NCT01455233
View directory record Official record
Conditions
Corneal Health, Cataract Surgery
Interventions
besivance, vigamox
Drug
Lead sponsor
Ophthalmology Consultants, Ltd.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2011 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 2 Interventional Results available

Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis

NCT01119898
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
PENNSAID Gel, Vehicle
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
40 Years to 85 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Tucson, Arizona • Sacramento, California • Clearwater, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 4 Interventional

Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis

NCT02732314
View directory record Official record
Conditions
Dermatitis, Atopic, Eczema
Interventions
Investigational OTC Cream, Cosmetic Eczema Cream, 0.05% Desonide Cream, Placebo Cream
Drug · Other
Lead sponsor
Procter & Gamble Beauty
Industry
Eligibility
12 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 23, 2026, 6:48 AM EDT
Not listed Phase 4 Interventional

Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis

NCT01413763
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod cream 3.75%, Placebo cream
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Fort Meyers, Florida
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 23, 2026, 6:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects

NCT00864500
View directory record Official record
Conditions
Healthy
Interventions
Clobetasol Propionate 0.05% lotion, single exposure, Clobex TM 0.05% Lotion, single exposure
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 23, 2026, 6:48 AM EDT